Optimal Medical Therapy for Stable Ischemic Heart Disease in 2024: Focus on Blood Pressure and Lipids

Timothy Abrahams; Stephen J Nicholls; Adam J Nelson

doi:10.1016/j.mcna.2023.12.005

Optimal Medical Therapy for Stable Ischemic Heart Disease in 2024: Focus on Blood Pressure and Lipids

Med Clin North Am. 2024 May;108(3):441-453. doi: 10.1016/j.mcna.2023.12.005. Epub 2024 Jan 16.

Authors

Timothy Abrahams¹, Stephen J Nicholls¹, Adam J Nelson²

Affiliations

¹ Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia.
² Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia; Adelaide Medical School, University of Adelaide, Adelaide, South Australia. Electronic address: adam.nelson@monash.edu.

PMID: 38548456
DOI: 10.1016/j.mcna.2023.12.005

Abstract

Hypertension and dyslipidemia are 2 highly prevalent and modifiable risk factors in patients with stable ischemic heart disease. Multiple lines of evidence demonstrate that lowering blood pressure and low-density lipoprotein cholesterol improves clinical outcomes in patients with ischemic heart disease. Accordingly, clinical guidelines recommend intensive treatment targets for these high-risk patients. This article summarizes the pathophysiology, supporting evidence, and treatment recommendations for management of hypertension and dyslipidemia among patients with manifest ischemic heart disease and points to future research and unmet clinical needs.

Keywords: Hypertension; LDL-C; Lipids; Stable ischemic heart disease; Targets; Triglycerides.

Publication types

Review

MeSH terms

Blood Pressure
Cholesterol, LDL / therapeutic use
Dyslipidemias* / drug therapy
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Hypertension* / drug therapy
Myocardial Ischemia* / drug therapy
Risk Factors

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cholesterol, LDL